Public release date: 1-Apr-2013 [ | E-mail | Share ] Contact: Dwight Angell dwight.angell@hfhs.org 313-876-8709 Henry Ford Health System DETROIT In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumor. Specifically, the research team found that introducing genetic material produced by MSCs, significantly reduced a particularly resistant form of malignant brain tumor in living lab rats. "This is the first foray of its type in experimental cancer therapy, and it represents a highly novel and potentially effective treatment," says Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute and vice chairman of the Department of Neurology at Henry Ford Hospital. The research is published in the current issue Cancer Letters. "I think this is an important and very novel approach for the treatment of cancers, and in this particular case the treatment of glioma," says Dr. Chopp. "We have been at the forefront of developing microRNAs as a means to treat disease, such as cancer and neurological injury. "This study shows it is effective in the living brain, and may even lend itself to specific cancer therapy, … Continue reading →

1 April 2013 Last updated at 06:43 ET A specialist rehabilitation centre in Bath for people with brain injuries has been closed. The unit, at Bath's Royal National Hospital, shut on Sunday following a drop in demand for services. Councillors are now urging the government to reverse the decision and have written to the Health Secretary Jeremy Hunt. The hospital trust said the NHS would continue to treat the patients who need care elsewhere in the country. Peter Miles, elected public governor for the hospital, criticised the closure and said it may not be too late for the government to step in. Mr Miles said: "The local council was not informed of this decision until some time in January. "They have a statutory right to be informed early on so they can consult, so they're quite upset about this and they've referred it to the Secretary of State." The letter has been written by Bath and North East Somerset Council's wellbeing policy development and scrutiny panel. The Royal National Hospital for Rheumatic Diseases NHS Foundation Trust has previously said in a statement that the number of local patients they cared for was "really quite small at around 20 people a … Continue reading →

TEMPLE, Texas, April 1, 2013 /PRNewswire/ --ONE MIND for Research was presented a gift of $50,000 towards the organization, whose goal is to make advancements in brain injury and related diseases through collaboration and information sharing. The check was presented by Drayton McLane Jr., Chairman and CEO of MAT. The McLane family donation will benefit U.S. soldiers suffering from Post Traumatic Stress (PTS) and Traumatic Brain Injury (TBI), and other various brain diseases. General Peter Chiarelli, USA (Ret.) is the CEO of ONE MIND for Research. At the end of his 40-year military career, he retired as a distinguished four-star General. His service included designing and implementing American defense policy for the US Army and the Department of Defense during peace and war combat operations. "PTS is an injury, not a disorder," said Chiarelli. "There is much research that needs to be done and ONE MIND is working hard to ensure that this research is collected into a data base for all the best intellects in neuroscience to explore and find answers." The McLane family supports the mission of ONE MIND for Research, and hopes to shed light upon the reality of invisible war wounds that soldiers experience with PTS … Continue reading →

Apr. 1, 2013 In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumors. Specifically, the research team found that introducing genetic material produced by MSCs significantly reduced a particularly resistant form of malignant brain tumor in living lab rats. "This is the first foray of its type in experimental cancer therapy, and it represents a highly novel and potentially effective treatment," says Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute and vice chairman of the Department of Neurology at Henry Ford Hospital. The research is published in the current issue Cancer Letters. "I think this is an important and very novel approach for the treatment of cancers, and in this particular case the treatment of glioma," says Dr. Chopp. "We have been at the forefront of developing microRNAs as a means to treat disease, such as cancer and neurological injury. "This study shows it is effective in the living brain, and may even lend itself to specific cancer therapy, customized for the individual patient," Chopp adds. Chopp and his colleagues focused their efforts on glioma, by … Continue reading →